Abstract Body

Background: Assays that measure evolving biomarkers during HIV seroconversion are being used in cross sectional studies for HIV incidence estimation. The Bio-Rad Geenius™ HIV 1/2 Supplemental Assay has been developed for HIV-1 and HIV-2 antibody (Ab) confirmation and differentiation. It is a rapid (30 minute), immunochromatographic test that utilizes serum, plasma, finger stick or whole blood to detect HIV Ab. Single-use dual-path lateral flow cartridges include HIV-1 (p31, gp160, p24, p41)and HIV-2 (gp36, gp140) antigen bands and a protein A control band bound to the membrane solid phase, and protein A conjugated to colloidal gold dye particles for detection. Band intensities are captured by an automated reader enabling quantification of IgG Ab levels. Previous analysis by Bio-Rad of CEPHIA Developmental and Qualification Panels led to provisional criteria for interpretation of results for HIV incidence applications. Methodology: Geenius™ assays were performed on the 2500-member CEPHIA Evaluation Panel. This panel consists of clade diverse specimens from 918 individuals from the United States, Brazil and Africa, predominantly ART-naive, with estimable dates of infection (from 0-12 years), supplemented by “challenge” specimen sets from patients with factors predisposing to false recent results (elite controllers, suppressive ART, and AIDS). A Geenius™ recency index was calculated using HIV-specific band intensities for p31, gp41, and gp160 relative to the control band. Regression and frequency estimation were used to estimate mean duration of recent infection (MDRI: mean time, within 1-year post estimated exposure, that subjects return recent results) and false recent rate (FRR: proportion of recent test results among patients at least 1-year post infection). Results: Using the manufacturer’s cutoff for recent infection discrimination (index=1.5) the MDRI was calculated to be 157 (140.5-174.7) days. The FRR on eligible specimens was 8.9% [7.3-10.7%]. False recent misclassification was common in specimens from patients on suppressive ART (71.3% [65.7- 76.5%]) and from elite controllers (38.7% [28.8-49.4%]), but was uncommon in specimens from patients with AIDS or low CD4 counts (4.8% [2.7-7.9% CI] and 3.9% [1.8-7.2% CI] respectively). Weighting clinical stages among untreated individuals had no impact. Conclusions: This is the first evidence that the Geenius™ assay may be used as a method for identifying recent HIV infection. The MDRI and FRR presented here are similar to other currently used methods for recent HIV infection. The rapid test format allows for classification of recent infections at the same time that rapid HIV1/2 Ab confirmation and differentiation is performed.